PHIA Koninklijke Philips N.V.

Philips and Cognizant collaborate to introduce digital health solutions to providers, researchers, and patients

Philips and Cognizant collaborate to introduce digital health solutions to providers, researchers, and patients



Alliance Pairs Cloud-Based Healthcare Platform with Experience-Oriented Application Design to Improve Patient Care and Clinical Trials Through Increased Provider-Patient Connectivity

AMSTERDAM, THE NETHERLANDS and TEANECK, NJ – July 8, 2021 –  (NYSE: PHG, AEX: PHIA), a global leader in health technology, and (Nasdaq: CTSH), a world-leading professional services firm, today announced a new collaboration to develop end-to-end digital health solutions that will enable healthcare organizations and life sciences companies to improve patient care and accelerate clinical trials. The strategic alliance brings together Philips HealthSuite, a cloud-based platform and Cognizant’s digital engineering expertise to deliver and maintain leading-edge digital health solutions at scale, providing advanced connectivity and using big data to create actionable insights.

, built on Amazon Web Services, is an integrated, modular set of standards-based capabilities that support the development of digital health propositions. The platform securely stores critical healthcare data and provides both advanced data analytics and AI capabilities, while delivering industry-leading interoperability, connectivity, and regulatory compliance. To date, more than 100 types of medical devices have been integrated into HealthSuite, with over 145 billion clinical images securely archived on the cloud platform.

As part of this collaboration, Cognizant will build, deploy, implement, and operate client-specific applications on Philips HealthSuite. These customizable, scalable solutions integrate advanced data analytics, helping to improve both the patient and clinician experience by providing relevant data to the appropriate point-of-care.

With these solutions, healthcare providers can monitor their patients outside traditional clinical settings, and patients can stay more informed of their own well-being. In addition, both biopharmaceutical and medical device manufacturers can quickly gain actionable insights through advanced analytics to make more informed clinical development decisions and rapidly bring new solutions to patients.

“Despite advances, patients and clinicians still face a fragmented technology and data landscape that holds back innovative healthcare services which improve care quality and the human experience,” said Shez Partovi, Chief Innovation & Strategy Officer, Royal Philips. “Philips is committed to driving the digital transformation of healthcare. Partnering with Cognizant’s experienced digital engineering teams will accelerate the adoption of solutions built on Philips HealthSuite, delivering digital solutions across the healthcare continuum in a secure and compliant manner, and ultimately helping guide better health decisions for patients.”

For Life Sciences companies, Philips HealthSuite’s compliant and secure medical device connectivity, data integration and analysis will also benefit remote patient monitoring and decentralized clinical trials. This will enable a reduction in paperwork, help researchers reach more diverse trial participants, and improve connectivity between investigators and participants – with the goal of improving the quality and speed of therapy development.

“Cognizant and Philips are each dedicated to improving people’s lives through health technology,” said Ursula Morgenstern, President of Global Growth Markets at Cognizant. “This new collaboration will provide critical solutions that help manage the growing amount of health data available, keep patients and providers better connected, and help accelerate life-saving therapies to market. Virtual and digital health solutions are fundamental to improving health awareness and engagement. We are proud to work with Philips, a world leader in healthtech, to support the health and well-being of people everywhere.”

Learn More:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 17.3 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at .

About Cognizant

Cognizant (Nasdaq-100: CTSH) is one of the world’s leading professional services companies, transforming clients’ business, operating and technology models for the digital era. Our unique industry-based, consultative approach helps clients envision, build and run more innovative and efficient businesses. Headquartered in the US, Cognizant is ranked 185 on the Fortune 500 and is consistently listed among the most admired companies in the world. Learn how Cognizant helps clients lead with digital at or follow us @Cognizant.

For further information, contact:

Cognizant (US)

Josh Blumenthal

Cognizant (Europe, Asia-Pac)

Christina Schneider

Cognizant (India)

Rashmi Vasisht

Philips Global Press Office

Mark Groves

Attachments



EN
08/07/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

MDIC appoints Philips Chief Medical Officer Carla Goulart Peron as new...

MDIC appoints Philips Chief Medical Officer Carla Goulart Peron as new board member April 2, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Carla Goulart Peron, MD, Chief Medical Officer at Philips, has been appointed to the of the Medical Device Innovation Consortium (). Founded in 2012, MDIC is a unique public-private partnership that brings stakeholders across the medical device spectrum together with the US Food and Drug Administration () and other agency partners to help ensure patient access to medical device inn...

 PRESS RELEASE

FDA clears Philips AI solution that provides real-time guidance during...

FDA clears Philips AI solution that provides real-time guidance during complex minimally invasive heart valve repair March 26, 2026 Philips DeviceGuide uses AI to track and visualize mitral valve repair devices [1] in real time during minimally invasive procedures, supporting treatment [2]DeviceGuide integrates with Philips Azurion image-guided therapy platform that combines imaging, real-time data and intelligent software within a unified workflow to support more consistent, efficient and confidently guided minimally invasive procedures Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA...

 PRESS RELEASE

Philips launches IntraSight Plus to simplify coronary interventions an...

Philips launches IntraSight Plus to simplify coronary interventions and advance precision care March 25, 2026 Intuitive interventional cardiology platform combines the most comprehensive set of diagnostic and treatment planning tools to help support confident decisions and improved patient careWith FDA clearance and CE marking, IntraSight Plus streamlines the workflow efficiency of minimally invasive coronary procedures and can enable system operation time savings up to 47% in both the USA and Europe Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technolog...

 PRESS RELEASE

Philips remains No. 1 in Medtech at European Patent Office and the lar...

Philips remains No. 1 in Medtech at European Patent Office and the largest Dutch patent applicant March 24, 2026 Philips ranks No. 1 among medical technology companies in the European Patent Office Technology Dashboard 2025, filing 1,289 patent applications with the EPO in 2025.Philips’ platform-based solutions integrate hardware, software, data and AI to address clinical, operational and everyday health challenges.Philips’ innovation improved the lives of 2 billion people in 2025, with the goal of improving 2.5 billion lives per year by 2030, including 400 million people in medically unde...

 PRESS RELEASE

Philips convenes the Annual General Meeting of Shareholders 2026

Philips convenes the Annual General Meeting of Shareholders 2026 March 23, 2026 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has convened the Annual General Meeting of Shareholders (AGM) 2026 and published the agenda with explanatory notes. As previously announced, the agenda includes: Proposal to appoint John DeFord (American, 1962) as new member of the Supervisory Board, with effect from May 8, 2026.Proposals to re-appoint Paul Stoffels (Belgian, 1962), Herna Verhagen (Dutch, 1966) and Sanjay Poonen (American, 1969) as m...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch